<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742336</url>
  </required_header>
  <id_info>
    <org_study_id>B7451026</org_study_id>
    <secondary_id>2018-003579-36</secondary_id>
    <nct_id>NCT03742336</nct_id>
  </id_info>
  <brief_title>Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, 2-WAY CROSSOVER, SINGLE DOSE, OPEN LABEL STUDY TO ESTIMATE THE EFFECT OF PF-04965842 ON DABIGATRAN PHARMACOKINETICS IN HEALTHY PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, 2 way crossover, single dose, open label study of the effect&#xD;
      of PF 04965842 on dabigatran PK in healthy participants. Participants will be randomized to 1&#xD;
      of 2 treatment sequences as described below. A total of 20 healthy male and/or female&#xD;
      participants will be enrolled in the study so that 10 participants will be enrolled in each&#xD;
      treatment sequence. Each treatment sequence will consist of 2 periods that are each 3 days in&#xD;
      duration. The total duration of participation from the Screening Visit to Day 7 will be a&#xD;
      maximum of 35 days and from the Screening Visit to Follow-up Contact/Visit will be a maximum&#xD;
      of 70 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2018</start_date>
  <completion_date type="Actual">February 18, 2019</completion_date>
  <primary_completion_date type="Actual">February 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCinf of dabigatran</measure>
    <time_frame>36 hours after dabigatran administration in Period 1 and 2</time_frame>
    <description>Area under the curve from time zero to extrapolated infinite time for dabigatran</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Cmax of dabigatran</measure>
    <time_frame>36 hours after dabigatran administration in Period 1 and 2</time_frame>
    <description>Maximum observed plasma concentration for dabigatran</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast of dabigatran</measure>
    <time_frame>36 hours after dabigatran administration in Period 1 and 2</time_frame>
    <description>Area under the plasma concentration time curve from 0 to the time of last measurement of dabigatran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of dabigatran</measure>
    <time_frame>36 hours after dabigatran administration in Period 1 and 2</time_frame>
    <description>Time to maximum concentration of dabigatran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of dabigatran</measure>
    <time_frame>36 hours after dabigatran administration in Period 1 and 2</time_frame>
    <description>apparent terminal half life of dabigatran</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events (AEs).</measure>
    <time_frame>Screening up to 28-35 days after the last dose of PF 04965842 in period 2</time_frame>
    <description>Number of subjects with adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with laboratory tests findings of potential clinical importance</measure>
    <time_frame>Screening through Day 3 of period 2</time_frame>
    <description>Number of subjects with laboratory tests findings of potential clinical importance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant abnormal vital signs</measure>
    <time_frame>Screening through Day 3 of period 2</time_frame>
    <description>Number of subjects with clinically significant abnormal vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant abnormal ECGs</measure>
    <time_frame>Screening through Day 3 of period 2</time_frame>
    <description>Number of subjects with clinically significant abnormal ECGs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of dabigatran on Day 1 of Period 1 and Single dose of dabigatran + PF-04965842 on Day 1 of Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of dabigatran + PF-04965842 on Day 1 of Period 1 and Single dose of dabigatran on Day 1 of Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04965842</intervention_name>
    <description>Single oral 200 mg dose of PF-04965842</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Single 75 mg dose of dabigatran</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants are eligible to be included in the study only if all of the following criteria&#xD;
        apply:&#xD;
&#xD;
        Age and Sex:&#xD;
&#xD;
          1. Male and female participants must be 18 to 55 years of age, inclusive, at the time of&#xD;
             signing the informed consent document (ICD).&#xD;
&#xD;
             Type of Participant and Disease Characteristics:&#xD;
&#xD;
          2. Male and female participants who are overtly healthy as determined by medical&#xD;
             evaluation including a detailed medical history, complete physical examination,&#xD;
             laboratory tests, and ECG.&#xD;
&#xD;
          3. Participants who are willing and able to comply with all scheduled visits, treatment&#xD;
             plan, laboratory tests, lifestyle considerations, and other study procedures.&#xD;
&#xD;
             Weight:&#xD;
&#xD;
          4. Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
             Informed Consent:&#xD;
&#xD;
          5. Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent document (ICD) and in&#xD;
             this protocol.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
        Medical Conditions:&#xD;
&#xD;
          1. Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic (including alcoholic liver&#xD;
             disease, nonalcoholic steatohepatitis (NASH), autoimmune hepatitis, and hereditary&#xD;
             liver diseases), psychiatric, neurological, or allergic disease (including drug&#xD;
             allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of&#xD;
             dosing).&#xD;
&#xD;
          2. Evidence or history of clinically significant dermatological condition (eg, atopic&#xD;
             dermatitis or psoriasis) or visible rash present during physical examination.&#xD;
&#xD;
          3. Participants, who according to the product label for dabigatran, would be at increased&#xD;
             risk if dosed with dabigatran.&#xD;
&#xD;
          4. Risks of bleeding including prior personal or familiar history of abnormal bleeding,&#xD;
             hereditary or acquired coagulation or platelet disorder or abnormal coagulation test&#xD;
             (prothrombin time [PT]/international normalized ratio [INR] or partial thromboplastin&#xD;
             time [PTT]/activated partial thromboplastin time [aPTT] greater than upper limit of&#xD;
             normal [ULN]) result at screening.&#xD;
&#xD;
          5. Surgery planned within 4 weeks after the end of the study.&#xD;
&#xD;
          6. Self reported history or risk factors for QT prolongation or torsades de pointes (eg,&#xD;
             organic heart disease, congestive heart failure, hypokalemia, hypomagnesaemia,&#xD;
             congenital long QT syndrome, myocardial ischemia or infarction), congenital deafness,&#xD;
             family history of sudden death, and family history of long QT syndrome.&#xD;
&#xD;
          7. Any condition possibly affecting drug absorption (eg, gastrectomy).&#xD;
&#xD;
          8. History of human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus&#xD;
             infection; positive testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis&#xD;
             B core antibody (HepBcAb), or hepatitis C antibody (HCVAb).&#xD;
&#xD;
             As an exception, a positive HepBsAb as a result of participant vaccination is&#xD;
             permissible.&#xD;
&#xD;
          9. Other acute or chronic medical or psychiatric condition including recent (within the&#xD;
             past year) or active suicidal ideation or behavior or laboratory abnormality that may&#xD;
             increase the risk associated with study participation or investigational product&#xD;
             administration or may interfere with the interpretation of study results and, in the&#xD;
             judgment of the investigator, would make the participant inappropriate for entry into&#xD;
             this study.&#xD;
&#xD;
             Prior/Concomitant Therapy:&#xD;
&#xD;
         10. Use of prescription or nonprescription drugs and dietary and herbal supplements within&#xD;
             7 days or 5 half lives (whichever is longer) prior to the first dose of&#xD;
             investigational product.&#xD;
&#xD;
             Prior/Concurrent Clinical Study Experience:&#xD;
&#xD;
         11. Previous administration with an investigational drug within 30 days (or as determined&#xD;
             by the local requirement) or 5 half lives preceding the first dose of investigational&#xD;
             product used in this study (whichever is longer).&#xD;
&#xD;
             Diagnostic Assessments:&#xD;
&#xD;
         12. A positive urine drug test.&#xD;
&#xD;
         13. Screening supine systolic blood pressure (BP) &lt;90 mm Hg or &gt;=140 mm Hg following at&#xD;
             least 5 minutes of supine rest; OR Screening supine diastolic BP &lt;50 mm Hg or &gt;=90 mm&#xD;
             Hg following at least 5 minutes of supine rest.&#xD;
&#xD;
             If a participant meets any of these criteria, the BP should be repeated 2 more times&#xD;
             and the average of the 3 BP values should be used to determine the participant's&#xD;
             eligibility.&#xD;
&#xD;
         14. Screening supine 12 lead ECG demonstrating:&#xD;
&#xD;
               -  QTcF &gt;450 msec; OR&#xD;
&#xD;
               -  QRS interval &gt;120 msec. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the&#xD;
                  ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values&#xD;
                  should be used to determine the participant's eligibility.&#xD;
&#xD;
         15. Participants with ANY of the following abnormalities in clinical laboratory tests at&#xD;
             screening, as assessed by the study specific laboratory and confirmed by a single&#xD;
             repeat test, if deemed necessary:&#xD;
&#xD;
               -  Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT)&#xD;
                  or alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT)&#xD;
                  level &gt;=1.5 Ã— ULN;&#xD;
&#xD;
               -  Total bilirubin level &gt; ULN; participants with a history of Gilbert's syndrome&#xD;
                  may have direct bilirubin measured and would be eligible for this study provided&#xD;
                  the direct bilirubin level is &lt;=ULN;&#xD;
&#xD;
               -  PT/INR or PTT/aPTT &gt; ULN;&#xD;
&#xD;
               -  Estimated creatinine clearance &lt;90 mL/min.&#xD;
&#xD;
             Other Exclusions:&#xD;
&#xD;
         16. History of regular alcohol consumption exceeding 14 drinks/week for female&#xD;
             participants or 21 drinks/week for male participants (1 drink = 5 ounces [150 mL] of&#xD;
             wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6&#xD;
             months before screening.&#xD;
&#xD;
         17. Known relevant history of elevated liver function tests (LFTs).&#xD;
&#xD;
         18. History of tuberculosis (TB) (active or latent) or inadequately treated TB infection.&#xD;
             Positive QuantiFERON - TB Gold test.&#xD;
&#xD;
         19. Any history of chronic infections, any history of recurrent infections, any history of&#xD;
             latent infections, or any acute infection within 2 weeks of baseline.&#xD;
&#xD;
         20. History of disseminated herpes zoster, or disseminated herpes simplex, or recurrent&#xD;
             localized dermatomal herpes zoster.&#xD;
&#xD;
         21. History of sensitivity to heparin or heparin induced thrombocytopenia.&#xD;
&#xD;
         22. Use of tobacco or nicotine containing products in excess of the equivalent of 5&#xD;
             cigarettes per day.&#xD;
&#xD;
         23. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more&#xD;
             within 60 days prior to first dose of investigational product.&#xD;
&#xD;
         24. History of hypersensitivity to dabigatran.&#xD;
&#xD;
         25. Unwilling or unable to comply with the criteria in the Lifestyle Considerations&#xD;
             section of this protocol.&#xD;
&#xD;
         26. Have any malignancies or have a history of malignancies with the exception of&#xD;
             adequately treated or excised non metastatic basal cell or squamous cell cancer of the&#xD;
             skin, or cervical carcinoma in situ.&#xD;
&#xD;
         27. Investigator site staff members directly involved in the conduct of the study and&#xD;
             their family members, site staff members otherwise supervised by the investigator, or&#xD;
             Pfizer employees, including their family members, directly involved in the conduct of&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7451026</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Abrocitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

